Gilead Sciences, Inc. announced plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will ...

The FDA recently granted Fast Track designation to Assembly Biosciences, Inc’s novel treatment for patients with chronic hepatitis B virus (HBV) infection. The drug, ABI-H0731, is the manufacturer’s lead oral HBV core inhibitor, according to a press release.

These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic HCV infection. They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 2016. The ...

For 6 years in the Russian Federation, 178 permits have been issued for the clinical trials of medications for the treatment and prevention of HIV/AIDS. This is seven times more than in the previous six years, from 2006 to 2011, when 25 studies were approved. While ...

Alexei Zelenev and colleagues presented an elegant analysis of treatment-as-prevention (TasP) for hepatitis C virus (HCV) infection in people who inject drugs (PWID), using a model capturing the dynamics of the injecting-partnership network, which is superior to the more common approaches of compartmental modelling (omitting ...

This first Action plan for viral hepatitis in the WHO European Region adapts the Global Health Sector Strategy on Viral Hepatitis, 2016–2021 to the context of the European Region.

Medicines will be provided to Kazakh patients free of charge.

Since the last epidemiological update on this multi-country hepatitis A outbreak published on 29 September 2017, 22 EU/EEA countries (Austria, Belgium, Croatia, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Luxembourg, Malta, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden and the ...

The drug was approved in India in November this year and is the “first” to be approved in eight years for the management of this infection here, Mylan added.

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to a sustained response in all people with HIV and genotype 1 or 4 hepatitis C virus (HCV) in the SWIFT-C study, according to a report at the AASLD Liver Meeting last month in Washington, DC.

16 non-governmental organizations from different regions of the country will participate in the European initiative aimed at encouraging people to get tested for HIV and hepatitis, including the members of the “Consortium of Key Communities” representing Ukraine in the ECUO PLWH. The European HIV-Hepatitis Testing Week will ...

MSF said the deals with generic companies meant it was now able to provide a 12-week course of treatment for around $120, against $1,400 to $1,800 available through Gilead and BMS access programs for poorer nations.

Nine countries — Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, the Netherlands and Qatar — are on course to eliminate hepatitis C by 2030, according to data released at the World Hepatitis Summit in São Paulo, Brazil, this week.

Access to treatment should be increased worldwide and cover 80% of patients by 2030.

In 2015, viral hepatitis caused the death of 1 million 340 thousand people around the world. Such data are published in the report of the World Health Organization, during the International Congress on diseases of the liver ILC 2017 held in Amsterdam. One of the causes of high mortality is the ...

AbbVie’s new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. Glecaprevir/pibrentasvir (Maviret) is expected to be approved ...

WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories ...

Released in advance of the 9th IAS Conference on HIV Science convening next week in Paris, our 2017 report continues to demonstrate the significant yields of drugs and biologics research and the advancement of breakthrough technologies that aim to detect, prevent, treat or cure HIV, tuberculosis ...